stockrowEvolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024.
- Revenue
- +13.0%
- EPS
- +20.8%
- Free cash flow
- +77.7%
- Total debt
- +7.63%
Quarter to September 2026, against a year earlier
Follow EOLS
Alert me
Evolus, Inc. (EOLS) EV/Sales
As of 5 November 2026, Evolus, Inc. (EOLS) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 0.0× (March 2020) to 10.0× (March 2021); the current reading is higher than 30% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (32.78%) |
| FY2024 | 3.0× | (14.02%) |
| FY2023 | 3.5× | (3.04%) |
| FY2022 | 3.6× | 10.20% |
| FY2021 | 3.2× | 51.99% |
| FY2020 | 2.1× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.2× | 8.53% |
| Jun 2026 | 2.0× | 36.69% |
| Mar 2026 | 1.5× | (25.75%) |
| Dec 2025 | 2.0× | (0.25%) |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. compare | 0.5× |
| EVO Evotec AG compare | 0.7× |
| ACB Aurora Cannabis Inc. compare | 1.3× |
| KMDA Kamada Ltd. compare | 1.8× |
| EOLS Evolus, Inc. | 2.0× |
| COLL Collegium Pharmaceutical, Inc. compare | 2.1× |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 2.9× |
| AQST Aquestive Therapeutics, Inc. compare | 8.5× |
| TKNO Alpha Teknova, Inc. compare | 9.2× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)